Nabriva Therapeutics (NASDAQ:NBRV) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV) in a research report report published on Wednesday morning. The firm issued a hold rating on the biotechnology company’s stock.

Nabriva Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.12, a current ratio of 0.85 and a quick ratio of 0.52. Nabriva Therapeutics has a twelve month low of $1.22 and a twelve month high of $8.45. The stock has a market capitalization of $45.46 million, a P/E ratio of 0.00 and a beta of 1.53.

About Nabriva Therapeutics

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration.